atazanavir (Reyataz)
Title: atazanavir (Reyataz)Category: MedicationsCreated: 7/17/2003 12:00:00 AMLast Editorial Review: 8/22/2019 12:00:00 AM (Source: MedicineNet HIV General)
Source: MedicineNet HIV General - August 22, 2019 Category: Infectious Diseases Source Type: news
Medical News Today: What are protease inhibitors for HIV?
Protease inhibitors are a class of HIV medication. They block the function of HIV protease enzymes. Taken with other antiretroviral drugs, protease inhibitors help prevent HIV from multiplying. Brand names include Reyataz, Prezista, and Lexiva. Learn about the actions and side effects of protease inhibitors here. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 3, 2018 Category: Consumer Health News Tags: HIV and AIDS Source Type: news
Reyataz (Atazanavir Sulfate) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - June 5, 2017 Category: Drugs & Pharmacology Source Type: news
FDA Updates Atazanavir Oral Powder Label
"On September 24, 2015, FDA approved revisions to the Reyataz (atazanavir) oral powder label to include dosing recommendations for patients three months and older weighing at least 5 kg. This represents the addition of a new pediatric weight band. Previously the oral powder formulation was for patients three months and older weighing at least 10 kg.
"Reyataz oral powder must be taken with ritonavir and is not recommended for use in children who weigh less than 5 kg."
The updated labeling will be available at the FDA website.
More information is available:
FDA: Press release
AIDSinfo: Patient f...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - October 9, 2015 Category: Infectious Diseases Source Type: news
View AIDSinfo Patient Fact Sheets on Three Recently Approved HIV Medications
AIDSinfo invites you to view our patient fact sheets on three medications recently approved by the FDA. The three medications are all indicated for use in the treatment of HIV infection in adults. The patient fact sheets include information on dosage forms and strengths, possible side effects, and instructions on how to take and store the medications.
Fact sheet on abacavir/dolutegravir/lamivudine (brand name: Triumeq)
Triumeq is a combination medicine that can be used alone as a complete treatment regimen or with other HIV medicines.
Fact sheet on cobicistat (brand name: Tybost)
Cobicistat is ...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - October 24, 2014 Category: Infectious Diseases Source Type: news
New Pediatric Dosage Form and Label Changes for Reyataz (Atazanavir)
"On June 2, 2014, FDA approved a new dosage form, Reyataz (atazanavir) oral powder for use in combination with other antiretroviral agents for the treatment of HIV-1, in patients over 3 months of age and between 10 kg to < 25 kg. The first part of this announcement summarizes the changes relevant to the oral formulation and use in pediatric patients. The second part summarizes other general changes to the label."
The updated labeling for atazanavir is available at the FDA website.
More information is available:
FDA: Press release
AIDSinfo: Patient fact sheet on atazanavir (Source: AIDSinfo...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - June 20, 2014 Category: Infectious Diseases Source Type: news
BMS Files Reyataz-Cobicistat Combo Tablet NDA For HIV-1
Bristol-Myers Squibb announced the filing of a New Drug Application for the fixed-dose combination tablet of atazanavir sulfate (marketed under the brand name Reyataz) with cobicistat for the treatment of patients with HIV-1. (Source: Pharmaceutical Online News)
Source: Pharmaceutical Online News - April 15, 2014 Category: Pharmaceuticals Source Type: news
FDA Updates Atazanavir Sulfate Capsule Labeling
“Recently [February 4, 2013] FDA approved changes to the Reyataz (atazanavir sulfate) capsule labeling to include the following changes.
“Section 5 Warnings and Precautions was revised to include cholelithiasis ...
“In section 6 Adverse Reactions: Postmarketing Experience, interstitial nephritis was added.
“In section 7 Drug Interactions: information regarding coadministration with boceprevir, carbamazepine, phenytoin, phenobarbital, lamotrigine and voriconazole was added.”
The updated labeling will be available at the FDA website.
More information is available:
FDA: Press rele...
Source: AIDSinfo At-a-Glance: Offering Information on HIV/AIDS Treatment, Prevention, and Research, A Service of the U.S. Department of Health and Human Services (DHHS) - February 12, 2013 Category: Infectious Diseases Source Type: news
